4à6 BioAlps: Medtronic/Kyphon (February 16th, 2010, Neuchâtel)You are hereA propos de BioAlpsGalerie photosPhotos d'archives4à6 BioAlps: Medtronic/Kyphon (February 16th, 2010, Neuchâtel)4à6 BioAlps: Medtronic/Kyphon (February 16th, 2010, Neuchâtel)
Find an actor
4à6 de BioAlps - Tornos15.03.2018Les "4à6" de BioAlps sont une série d'événements organisés dans chacun des 7 cantons de Suisse occidentale.
Allergan is seeking new partnershipsAllergan wishes to extend their project portfolio in biopolymers for medical injectable and/or implantable...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.